ees Europe: Battery Storage – Powerbanks for the Energy Transition
4.6.2024 15:49:00 EEST | Business Wire | Press release
Battery storage is booming. According to a study by Frontier Economics, the volume of grid-connected storage in Germany alone could increase to 60 gigawatts (GW) or 271 gigawatt-hours (GWh) by 2050. This is forty times the current storage capacity. Similar dynamics in cost reduction and installation speed are expected as seen with photovoltaics (PV) in recent years. Soon, battery storage will fundamentally change energy supply. The latest technologies, trends, and market developments will be showcased at ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems. It will take place from June 19 to 21 as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry, in Munich. Around 3,000 exhibitors and over 115,000 visitors from around the world are expected in 19 exhibition halls and an outdoor area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604806032/en/
Innovations in the field of large-scale storage can be seen at this year’s ees Europe. (Photo: Business Wire)
The growth of grid-connected storage brings enormous advantages to the energy system and offers economic benefits. The expansion of large-scale storage can significantly reduce the need for new gas power plant investments in Germany by up to 9 GW. This expansion also contributes significantly to reducing CO2 emissions. The key point: this growth is purely market-driven and does not rely on government subsidies.
Short-term storage enables system transformation
Battery storage increasingly assumes critical roles in ensuring a reliable power supply and stabilizing power grids. Large battery storage systems ensure voltage control, provide immediate reserve capacity, and facilitate black start capability, playing a part in congestion management. They can balance fluctuations in the grid within seconds and store energy for hours or days. The black start capability of storage systems is crucial in emergencies.
Moreover, storage systems can mitigate the effects of delayed grid expansion. They help optimize the utilization of the limited grid infrastructure, allowing more facilities to be connected. This enables more capacity and additional PV installations despite limited grid connection capacity. Another benefit: battery storage increases the market value of renewable energy. Green electricity can be stored when market prices are low and fed into the grid when demand is high and electricity prices are correspondingly high.
International storage revolution
Worldwide, exponential growth in battery storage is evident. Experts predict that global production capacity will rise to 500 GWh per year by 2025. In markets such as Australia, the USA, and India, tenders for new wind or solar capacities have been coupled with storage for years. In Germany, the speed of expansion and the installed storage capacity are still modest. However, this year, battery storage systems in Germany will surpass pumped storage systems in installed capacity for the first time.
Setting the right framework
To make stationary storage of all sizes attractive, a favorable market environment and simple regulations are needed. Market-driven expansion must continue to be enabled and improved. Modern framework conditions for battery storage should be set through reforms in grid fees, flexible electricity tariffs, or the introduction of contracts for difference.
ees Europe
Every year, ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, provides a networking opportunity for the industry’s key players – all under the motto “Innovating Energy Storage”. It focuses on the latest technologies, trends and market developments. ees Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.
For more information: www.ees-europe.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604806032/en/
Contact information
ressourcenmangel an der Panke GmbH
Roberto Freiberger
roberto.freiberger@ressourcenmangel.de
Solar Promotion GmbH
Peggy Zilay
zilay@solarpromotion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom